Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2024

  • ID: 4497324
  • Report
  • Region: Global
  • 480 Pages
  • Kuick Research
1 of 5


  • Abraxis BioScience
  • Amgen
  • Cadila Healthcare
  • Genzyme Corporation
  • NanoCarrier
  • Pfizer
  • MORE

Report Highlights:

  • Nanoparticle Drug  Market: US$ 200 Billion Opportunity By 2024
  • Global Pipeline For Nanoparticle Drug: 231 Drugs
  • Drugs In & Above Phase II Trials: 33 Drugs
  • Marketed Nanoparticle Drugs: 13 Drugs
  • Dosage, Price & Patent Analysis Of Key Drugs
  • Upcoming Nanoparticle Drug Delivery Techniques
  • Global Nanoparticle Drug Clinical Pipeline by Company, Indication & Phase

Drug delivery plays a significant role in determining the therapeutic outcome of a treatment. The limitations of conventional drug delivery system such as low bioavailability of therapeutics, poor patient compliance and fluctuation in concentration has led to a dire need for the development of new, better and safer delivery method with enhanced therapeutic outcome and safety.

The practice of drug delivery has changed dramatically in the past few decades with substantial changes being anticipated in the future. An emerging method that clearly stands out is the use of nanotechnology in drug delivery which utilizes specially designed nanoparticles to enhance drug delivery more effectively and precisely with additional advantages such as longer circulation delivery, longer half-lives, better bioavailability, improved pharmacokinetics and reduced side effects.

Additionally, nanoparticles also have the ability to transport drug molecules across the blood brain barrier which can be exploited to develop revolutionizing therapeutics for clinical conditions such as Parkinson's disease, Alzheimer's disease, schizophrenia and depression. It has also raised hope in complex disease like brain tumor – which is currently impossible to treat with conventional drug delivery methods.

An insight into the market trends shows that the ability of nanoparticles to enhance therapeutic outcome by a significant margin has led pharmaceutical companies to develop nanoparticle formulation of popular drugs like Megace ES(Enhanced Stability), Estrasorb (estradiol topical emulsion)and Triglide(Nanocrystal formulation of Tricor). Nanoparticle formulations of popular cancer therapeutics like Doxorubicin and Taxol has also been well received in the cancer therapeutic segment due to longer half-lives and reduced side effects.

Advancement in nanotechnology has resulted in the entry of many types of nanoparticles in the market. Nanocrystal and liposomes are currently the most popular nanoparticles in use, followed by micelles and dendrimers. Nanocrystal, liposomal and micelle formulations of therapeutics are being developed and marketed which is bound to increase the market size in the future.

Geographical Analysis of the Nanoparticle drug delivery method projects the increasing dominance of US with more than 40% of the global market, followed by Europe. However, the market size is anticipated to increase in the Asia Pacific and Latin American region during the forecast period due to multiple growth factors supporting the analysis, such as increase in patient base and the rising interest of key players like Johnson & Johnson and Novartis in the region.

The Research Estimates the Global nanoparticle drug market to reach over US$ 200 Billion by 2024 at a CAGR of 10%. Growth promoting factors like increase in global prevalence of various clinical indications like cancer, diabetes and rheumatoid arthritis are bound to fuel the market growth with oncology being the dominant segment. The increasing demand for effective treatment methods to provide for the rising pool of patients are expected to help the segment retain dominance over the report’s forecast period as well.

The nanoparticles drug delivery market however faces some major challenges that are anticipated to hamper with its future growth. High demand of investments, scientific and technical limitations and overcrowding of vendors and marketing challenges such as exorbitant pricing of therapeutics, limited market penetration and low awareness are hurdles that need to be taken care of to enhance the potential of nanoparticle drug delivery segment.

This Research report on global nanoparticle drug delivery market provides an in-depth analysis of the market with special emphasis on the Global market size, current market trends, dynamics and other factors that might have an impact on the market. Comparative price, dosage and therapy cost analysis of Original drugs with Nanoparticle formulations analyses the promising potential of Nanoparticle drug delivery, ultimately proving its superiority. The Research analysis is based on extensive research from both primary and secondary sources, highlighting the market opportunities regionally and ensuring an optimistic future forecast of the global nanoparticles drug delivery market.

Note: Product cover images may vary from those shown
2 of 5


  • Abraxis BioScience
  • Amgen
  • Cadila Healthcare
  • Genzyme Corporation
  • NanoCarrier
  • Pfizer
  • MORE

1. Nanoparticles – Revolutionizing Drug Delivery Method
1.1 Prologue to Targeted Drug Delivery by Nanoparticles
1.2 Nanoparticle Drug Delivery –Enhancing the Efficacy of Therapeutics by Nanotechnology

2. Need for Nanoparticle Drug Delivery
2.1 Limitations of Traditional Drug Delivery Techniques
2.2 Rising Demand for Better Targeted Drug Delivery Techniques in the Oncology Segment

3. Superiority of Nanoparticle Based Drug Delivery over Traditional Drug Delivery
3.1 Better Therapeutic Outcome than Conventional Drug Delivery Methods
3.2 Role of Nanoparticles in Better Diagnosis of Cancer

4. Importance of Nanoparticle Drug Delivery in Cancer Therapy
4.1 Wide Application of Nanoparticles in Cancer Therapy
4.2 Mechanisms of Nanoparticle Internalization in Cancer Cells for Imaging & Therapy

5. Existing Techniques For Nanoparticle Drug Delivery
5.1 Nanocrystals
5.2 Liposomes
5.3 Dendrimers
5.4 Micelle Based Drug Delivery

6. Upcoming Nanoparticle Drug Delivery Techniques
6.1 Polymeric Nanoparticles
6.2 Metal based Nanoparticles (Gold, iron oxide)
6.3 Fullerenes & Carbon Nanotube
6.4 Quantum Dots Delivery

7. Global Nanoparticle Drug Market Overview
7.1 Current Market Scenario
7.2 Global Nanoparticle Drug Clinical Pipeline Overview

8. Price & Dosage Analysis of Commercially Available Nanoparticle Therapeutics
8.1 Liposomal Doxorubicin
8.1.1 Availability, Price & Mechanism of Action
8.1.2 Dosage in Various Clinical Indications
8.1.3 Liposomal Doxorubicin (Nanoparticle) v/s Traditional Doxorubicin – Comparative Analysis
8.2 Amphotericin
8.2.1 Availability, Price & Mechanism of Action
8.2.2 Dosage by Indication
8.2.3 Comparative Analysis- Conventional Amphotericin B v/s Nanoparticle Formulations
8.3 Paclitaxel (Taxol, Onxal)
8.3.1 Availability,Price & Mechanism of Action
8.3.2 Dosage Analysis in Various Types of Cancer
8.3.3 Paclitaxel v/s Abraxane(liposomal)
8.4 Sirolimus (Rapamune)
8.4.1 Availability,Price & Mechanism of Action
8.4.2 Rapamune – Dosage Analysis
8.5 Emend (Aprepitant Nanocrystal)
8.5.1 Availability & Price
8.5.2 Dosage Analysis
8.6 Megace ES (Enhanced Stability)
8.6.1 Availability, Price & Mechanism of Action
8.6.2 Comparative Dosage Analyis – Megace v/s Megace ES
8.7 Estradiol Topical Emulsion(Estrasorb)
8.8 Other Nanoparticle Therapeutic Formulations
8.8.1 Feraheme
8.8.2 Triglide – Nanocrystal Version of Tricor

9. Nanoparticle Drug Delivery – Market Trend & Patent Distribution Analysis
9.1 Patent Filing Status in Nanoparticle Drug Delivery
9.2 Patent Distribution by Nanomaterial Type
9.3 Patent Distribution by Stimulus
9.4 Patent Distribution by Route of Administration & Forms of Drug Delivery

10. Driving Factors of Nanoparticle Drug Delivery Market
10.1 Increasing Prevalence of Disease & the Need for Better Therapeutics
10.2 Better Reliability & Safety than Conventional Therapeutics
10.3 Advancement in Research & Development
10.4 Promising Investment & Market Potential
10.5 Rapid Advancement in Innovative and Superior Technology

11. Challenging Aspects of Nanoparticle Drug Delivery Segment
11.1 Highly Expensive Technique & Nanoparticle Products
11.2 Scientific & Technical Limitation Related to Nanoparticles Drug Delivery
11.3 Regional Limitation & Low Market Penetrance
11.4 Dominance of Conventional Drug Delivery Segment

12. Future Forecast & Market Analysis of Global Nanoparticle Drug Delivery Market

13. Global Nanoparticle Drug Clinical Pipeline by Company, Indication & Phase
13.1 Unknown
13.2 Research
13.3 Preclinical
13.4 Clinical
13.5 Phase-I
13.6 Phase-I/II
13.7 Phase-II
13.8 Phase-II/III
13.9 Phase-III
13.10 Preregistration
13.11 Registered

14. Marketed Nanoparticle Drug Clinical Insight by Company & Indication
14.1 Rilpivirine (Edurant)
14.2 Albumin-Bound Paclitaxel (Abraxane, Coraxane & Coroxane)
14.3 Meloxicam (VIVLODEX)
14.4 Ferumoxytol (Feraheme & Rienso)
14.5 Paclitaxel Liposomal - Sun Pharma Advanced Research Company
14.6 Fenofibrate (Lipanthyl & TriCor)
14.7 Doxorubicin Liposomal (Caelyx & Doxil)
14.8 Vincristine Liposomal (Marqibo)
14.9 Fenofibrate (Triglide)
14.10 Rexin-G
14.11 Estradiol Topical (Estrasorb)
14.12 Glycyrrhiza/Phosphatidylcholine (Phosphogliv)
14.13 Paclitaxel Nanoparticle (Nanoxel)

15. Competitive Landscape
15.1 Abraxis BioScience
15.2 Access Pharmaceuticals
15.3 Alnylam Pharmaceuticals
15.4 Amgen
15.5 Arrowhead Research
15.6 BIND Therapeutics
15.7 Cadila Healthcare
15.8 Celegen Corporation
15.9 Celsion Corporation
15.10 Genzyme Corporation
15.11 Merck
15.12 NanoCarrier
15.13 Nippon Kayaku
15.14 Nanobiotix
15.15 Novavax
15.16 Pfizer
15.17 Roche
15.18 Samyang
15.19 Sanofi
15.20 Takeda Pharmaceutical

List of Figures:
Figure 1-1: Evolution of Nanoparticle Drug Delivery
Figure 1-2: Different Drug Delivery Routes
Figure 1-3: Organic Nanoparticles Used in Drug Delivery
Figure 2-1: Limitations of Traditional Drug Delivery Therapy
Figure 2-2: Global- Drug Delivery Segmentation by Route of Administration (%), 2017
Figure 3-1: Superior Characteristic of Nanoparticle Drug Delivery
Figure 3-2: Application of Nanoparticles in Diagnosis
Figure 4-1: Inorganic Nanoparticles Used in Drug Delivery
Figure 4-2: Nanoparticle - Application in Imaging Techniques (%), 2017
Figure 5-1: Nanoparticles Market Segmentation by Types
Figure 5-2: Global- Nanoparticle Drug Delivery Segmentation by Technology (%), 2017
Figure 5-3: Liposome Drug Delivery in Action
Figure 5-4: Dendrimer Nanoparticle in Drug Delivery
Figure 6-1: Gold Nanoparticles in Drug Delivery
Figure 6-2: Fullerenes Being Used as Vectors (Carrying Agents)
Figure 6-3: Quantum Dots in Cancer Therapy
Figure 7-1: Global Nanoparticle Drug Market (US$ Billion), 2013-2017
Figure 7-2: Global - Nanoparticle Drug Clinical Pipeline by Phase (%), 2018 till 2024
Figure 7-3: Global Nanoparticle Clinical Pipeline by Phase (%),2018 till 2024
Figure 8-1: Liposomal Doxorubicin - Availability by Concentration (ml)
Figure 8-2: Adriamycin - Price Analysis (US$/ml), 2018
Figure 8-3: Lipodox 50- Price Analysis (US$), 2018
Figure 8-4: Doxil- Dosage analysis for Ovarian Cancer (mg/m2)
Figure 8-5: Doxil - Dosage Analysis for Kaposi's sarcoma
Figure 8-6: Liposomal Doxorubicin - Dosage Analysis in Multiple Myeloma
Figure 8-7: Doxorubicin (Nanoparticle Variant)- Average Price Analysis (US$/ml), 2018
Figure 8-8: Comparative Dosage Analysis andndash; Traditional Doxorubicin v/s Liposomal Doxorubicin (mg/m2)
Figure 8-9: Doxorubicin- Comparative Price Analysis (US$/mg), 2018
Figure 8-10: Amphotericin B andndash; Availability by Concentration (mg/vial)
Figure 8-11: Conventional Amphotericin B- Dosage Analysis for  Adult Fungal Infections (mg/kg)
Figure 8-12: Amphotericin B - Dosage Analysis in Pediatric Fungal Infection (mg/kg)
Figure 8-13: Liposomal Amphotericin B- Dosage Analysis by Indication (mg/kg)
Figure 8-14: Amphotericin B andndash; Comparative Daily Dosage Analysis by Formulation (mg/kg), 2018
Figure 8-15: Amphotericin B-Comparative Price Analysis by Formulation per Day (US$), 2018
Figure 8-16: Comparative Price Analysis andndash; Amphotericin B Nanoparticle Formulations (US$), 2018
Figure 8-17: Paclitaxel - Availability by Concentration (mg and ml)
Figure 8-18: Paclitaxel - Working Mechanism
Figure 8-19: Abraxane- Dosage Analysis by Cancer (mg/Cycle)
Figure 8-20: Paclitaxel Dosage Analysis by Cancer (mg/m2)
Figure 8-21: Price Analysis- Paclitaxel v/s Abraxane (US$), 2018
Figure 8-22: Paclitaxel v/s Abraxane andndash;Comparative Positive Response Rate (%)
Figure 8-23: Rapamune - Availability of Formulations (mg)
Figure 8-24: Rapamune - Cost Analysis by Formulation (US$), 2018
Figure 8-25: Rapamune - Dosage for Low Immune Risk Patients (mg)
Figure 8-26: Rapamune - Dosage for High Immunologic Risk (mg)
Figure 8-27: Emend - Price and Availability (US$), 2018
Figure 8-28: Emend - Dosage Analysis (mg/day)
Figure 8-29: Dosage Analysis - Megace v/s Megace ES (mg/day)
Figure 8-30: Megace v/s Megace ES - Comparative Price Analysis (US$), 2018
Figure 8-31: Estrasorb- Price Analysis (US$), 2018
Figure 8-32: Feraheme - Dosage Analysis (mg/ml)
Figure 8-33: Triglide - Availability by Concentration (mg)
Figure 8-34: Comparative Price Analysis -Triglide and Tricor (US$/Pack), 2018
Figure 9-1: Global- Patent Analysis by Cancer Types (Number), 2016
Figure 9-2: Global andndash; Nanoparticle Patent Filing Status by Region (Numbers), 2016
Figure 9-3: Global- Patent Distribution by Material Type (Numbers), 2016
Figure 9-4: Stimulus of Nanoparticles to Various Factors
Figure 9-5: Global- Patent Distribution by Stimulus (Numbers), 2016
Figure 10-1: Nanoparticle Drug Delivery - Driving Factors
Figure 10-2: Global - Nanoparticle Research in Cancer Segment (By number)
Figure 10-3: Magnetic Nanoparticle - Recent Advances in Drug Delivery
Figure 11-1: Nanoparticle Drug Delivery Market Challenges
Figure 12-1: Global - Nanoparticle Drug Deliver Dominance by Region (%), 2017
Figure 12-2: Global- Nanoparticle Drug Market (US$ Billion), 2018-2024
Figure 12-3: Global- Gold Nanoparticles Future Forecast (US$ Million), 2018 - 2024
Figure 12-4: Global - Investments in the Nanoparticle Drug Delivery Segment (US$ Billion), 2013-2017
Figure 15-1: Arrowhead Research Corporation Clinical Pipeline
Figure 15-2: NanoCarrier Clinical Pipeline

List of Tables:
Table 5-1: List Of Commercially Available Nanocrystal Drugs and Their Indication
Table 5-2: Liposome Based Drugs - Current Status
Table 5-3: Current Market Status of Dendrimers
Table 6-4: Traditional Doxorubicin v/s Nanoparticle Doxorubicin

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Abraxis BioScience
  • Access Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Amgen
  • Arrowhead Research
  • BIND Therapeutics
  • Cadila Healthcare
  • Celegen Corporation
  • Celsion Corporation
  • Genzyme Corporation
  • Merck
  • NanoCarrier
  • Nippon Kayaku
  • Nanobiotix
  • Novavax
  • Pfizer
  • Roche
  • Samyang
  • Sanofi
  • Takeda Pharmaceutical
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown